Prevalence of Past and Reactivated Viral Infections and Efficacy of Cyclosporine A as Monotherapy or in Combination in Patients with Psoriatic Arthritis—Synergy Study: A Longitudinal Observational Study
Table 2
Description of treatments at baseline and at the end of study.
Baseline (number = 225)
From baseline to 12-month followup (number = 174)
Systemic treatments, number (%)
Cyclosporine
110 (48.9)
70 (40.2)
Cyclosporine + methotrexate
36 (16.0)
26 (14.9)
Cyclosporine + biologic
23 (10.2)
38 (21.8)
Cyclosporine + other systemic treatments
45 (20.0)
27 (15.5)
m.d.
11 (4.9)
13 (7.5)
Topic treatments, no. (%)1
Total number of patients treated
175 (77.8)
103 (59.2)
No topic treatment
47 (20.9)
68 (39.1)
m.d.
3 (1.3)
3 (1.7)
Corticosteroids
157 (69.8)
77 (44.3)
Vit D3 derivatives
98 (43.6)
53 (30.5)
Retinoids
27 (12.0)
8 (4.6)
PUVA
5 (2.2)
2 (1.1)
UVB
8 (3.6)
4 (2.3)
Laser
1 (0.4)
1 (0.6)
Other
15 (6.7)
21 (12.1)
Intra-articular injection
5 (2.2)
6 (3.4)
Patients might have been treated with more than one topic treatment. m.d.: missing data.
